T-cell therapy for KRAS G12D advanced cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new kind of treatment that uses your own immune cells (T cells) that are specially trained to find and attack cancer cells that have a KRAS G12D mutation. It's for people with advanced solid tumors that haven't been helped by standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have a specific change called KRAS G12D (confirmed by a special lab test).
- You must have a specific immune type (HLA-A11:01 or HLA-C08:02) on your white blood cells.
- Your cancer must be advanced or have spread and you have already received certain prior treatments depending on your cancer type (for example, colorectal cancer requires prior chemo with oxaliplatin and irinotecan).
- You cannot have had certain other treatments like certain gene therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
This trial tests a new cell therapy, DCTY1102, for people with advanced solid tumors like pancreatic, colorectal, or lung cancer who have tried other treatments. It uses your own immune cells that are modified to target a specific genetic change in your tumor.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a custom immune-cell treatment made from your blood that targets the KRAS G12V change in certain cancers. It is for people with advanced cancer who have already tried standard treatments, and it may help your immune system recognize and attack tumor cells.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.